Clovis Oncology tnitiates early access program for Rucaparib in Europe for ovarian cancer
Clovis Oncology announced the initiation of an early access program in Europe for rucaparib for treatment and as maintenance therapy in recurrent ovarian cancer. The program will be overseen and implemented by Caligor Coghlan, which specializes in early access to medicines. March 23, 2018